Skip to content
Search

Latest Stories

HRA Pharma celebrates 1st anniversary of Hana

HRA Pharma is celebrating the 1st anniversary of Hana, the first type of daily oral contraception available in the UK without a prescription.

The launch of Hana in 2021 followed the historic decision of the Medicines and Healthcare products Regulatory Agency (MHRA) to grant a marketing authorization and marked a significant step forward in the women’s contraception category.


The company reports that pharmacists have embraced the reclassification and have found merit in using emergency contraception consultations as an opportunity to educate women on their over-the-counter contraception options.

Alison Slingsby, innovations project manager at HRA Pharma, commented: “We have been delighted with Hana’s reception – within weeks of launch, it quickly became the best-selling mini-pill without prescription, with more than 95 per cent market share, and has maintained this market leading position ever since. We previously had the experience of switching emergency contraceptive ellaOne to a P medicine, Hana is on track to match and eventually exceed the ellaOne volumes.

"Pharmacists have embraced the new challenge of supplying regular daily contraception over the counter, engaging well with our comprehensive training resources, which they report have given them the knowledge and confidence to have more conversations about regular contraception with women. For instance, we have seen that pharmacies have had success incorporating Hana within emergency contraception consultations.”

Kate, a pharmacist from Somerset, explained: “During emergency hormonal contraception (EHC) consults, it is very useful when we discuss regular contraception to give them something to take away and to give them information on what can be sorted without seeing their GP. I had one girl who came back for Hana after she used EllaOne.”

Stephanie, a 21-year-old Hana user, said finding the right contraception has been a long journey and visiting a GP can flare her anxiety.

“I found going to a GP quite daunting – any social interaction like that, the dentist, the opticians… I don’t enjoy it at all. I’ve tried most contraception methods other than the coil but have discovered Hana and it’s so convenient; it works for me and my body. I think there should be a lot more in-depth information about contraception. Talking about it is important!”

Despite the progress made with introducing Hana as another choice, consumer research conducted by HRA Pharma shows women’s lingering dissatisfaction with their contraception. One in 10 women admit they are not satisfied with their current contraception, with one third (32 per cent) saying they have been searching the best contraceptive option for years.

As a leader in female reproductive healthcare, HRA Pharma has been working to broaden women’s access to contraception worldwide since its inception in 1996. The company is dedicated to highlighting women’s contraceptive choice and improving access across the board, an aim which continues into Hana’s second year on the market.

More For You

How community pharmacies can safely and profitably deliver high-quality NHS and private services

L-R: Baba Akomolafe, Rachna Chhatralia, Patricia Tigenoah-Ojo, and Raj Matharu

How community pharmacies are optimising services for a sustainable future

“Community pharmacy has come to a point where we have to change ourselves,” said Raj Matharu, CEO at Community Pharmacy South East London, and Superintendent Pharmacist of Westchem Pharmacy, as he opened a panel discussion at the recent Pharmacy Business Conference.

The 'Optimising Service Opportunities' session centred on how community pharmacies can safely and profitably deliver high-quality NHS and private services, while ensuring an excellent patient experience.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Janet Morrison discusses pharmacy funding strategy at 2025 conference

Health Secretary Wes Streeting outlines government support for community pharmacy

CPE calls new funding deal a ‘reluctant yes’

Community Pharmacy England (CPE) was “reluctant” to accept the new pharmacy funding deal due to the significant funding gap, said the organisation’s chief executive Janet Morrison, while recognising the settlement as the first step towards stabilising the sector.

Addressing the 2025 Pharmacy Business Conference on Sunday at London Hilton Wembley, Janet shared insights into the behind-the-scenes work that led to the agreement.

Keep ReadingShow less
RPS transition to Royal College

RPS transition to Royal College: What it means for pharmacy

RPS transition to Royal College: What it means for pharmacy - Professor Claire Anderson explains

The Royal Pharmaceutical Society (RPS) is set to transition into a Royal College after securing majority support from its members in a recent ballot. However, concerns have been raised about the long-term implications of this shift.

With a voter turnout of 31.4%, 6,144 out of 19,594 eligible members participated in the vote on the Royal Charter changes. Of those, 71.1% supported the transition, well above the required two-thirds majority for a Special Resolution Vote.

Keep ReadingShow less